244 related articles for article (PubMed ID: 4456974)
1. Variations in L-dopa absorption. Report of a parkinsonian patient with high plasma dopa concentration after therapeutical L-dopa dose.
Granerus AK; Jagenburg R; Rödjer S; Svanborg A
Acta Med Scand; 1974 Dec; 196(6):459-63. PubMed ID: 4456974
[No Abstract] [Full Text] [Related]
2. Intestinal decarboxylation of orally administered L-dopa. Influence of pharmacological preparations, dose magnitude, dose sequence and food intake.
Andersson I; Granerus AK; Jagenburg R; Svanborg A
Acta Med Scand; 1975 Nov; 198(5):415-20. PubMed ID: 1199816
[TBL] [Abstract][Full Text] [Related]
3. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
Mizuno Y; Yoshida M; Obayashi T; Ueki A
Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
[No Abstract] [Full Text] [Related]
4. [Results of determination of plasma methoxydopa in parkinsonian patients with or without dyskinesia induced by L-Dopa].
Perret J; Feuerstein C; Pellat J; Serre F; Gavend M; Tanche M
Rev Neurol (Paris); 1977 Nov; 133(11):627-36. PubMed ID: 601391
[TBL] [Abstract][Full Text] [Related]
5. Intermittent levodopa therapy in parkinsonism.
Koller WC
Adv Neurol; 1983; 37():45-50. PubMed ID: 6407286
[TBL] [Abstract][Full Text] [Related]
6. Homocysteine levels after acute levodopa intake in patients with Parkinson's disease.
Müller T; Kuhn W
Mov Disord; 2009 Jul; 24(9):1339-43. PubMed ID: 19425084
[TBL] [Abstract][Full Text] [Related]
7. Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease.
Blandini F; Fancellu R; Martignoni E; Mangiagalli A; Pacchetti C; Samuele A; Nappi G
Clin Chem; 2001 Jun; 47(6):1102-4. PubMed ID: 11375298
[No Abstract] [Full Text] [Related]
8. CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease.
Eldrup E; Mogensen P; Jacobsen J; Pakkenberg H; Christensen NJ
Acta Neurol Scand; 1995 Aug; 92(2):116-21. PubMed ID: 7484057
[TBL] [Abstract][Full Text] [Related]
9. [Long-term l-DOPA therapy for parkinsonism and its pathochemical aspect].
Petelin LS; Vartanian KZ; Romenskaia LKh
Zh Nevropatol Psikhiatr Im S S Korsakova; 1977; 77(12):1810-3. PubMed ID: 602554
[TBL] [Abstract][Full Text] [Related]
10. Peculiarities of L: -DOPA treatment of Parkinson's disease.
Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
[TBL] [Abstract][Full Text] [Related]
11. Amino acid and dopa levels in plasma and urine from L-dopa-treated patients with Parkinson's disease.
Hare TA; Vanna S; Beasley B; Chambers R; Vogel WH
J Lab Clin Med; 1971 Feb; 77(2):319-25. PubMed ID: 5540775
[No Abstract] [Full Text] [Related]
12. The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients.
Maruyama W; Naoi M; Narabayashi H
J Neurol Sci; 1996 Jul; 139(1):141-8. PubMed ID: 8836986
[TBL] [Abstract][Full Text] [Related]
13. [Effect of MK-486 alone on Parkinsonism; studies on the clinical symptoms and catecholamine concentrations in the blood, urine and cerebrospinal fluid].
Tohgi H; Ogawa M
No To Shinkei; 1977 Feb; 29(2):205-13. PubMed ID: 326277
[No Abstract] [Full Text] [Related]
14. The separation and identification of dopamine 3-O-sulfate and dopamine 4-O-sulfate in urine of Parkinsonian patients.
Bronaugh RL; Hattox SE; Hoehn MM; Murphy RC; Rutledge CO
J Pharmacol Exp Ther; 1975 Dec; 195(3):441-52. PubMed ID: 1195131
[TBL] [Abstract][Full Text] [Related]
15. Increased urinary morphine, codeine and tetrahydropapaveroline in parkinsonian patient undergoing L-3,4-dihydroxyphenylalanine therapy: a possible biosynthetic pathway of morphine from L-3,4-dihydroxyphenylalanine in humans.
Matsubara K; Fukushima S; Akane A; Kobayashi S; Shiono H
J Pharmacol Exp Ther; 1992 Mar; 260(3):974-8. PubMed ID: 1545408
[TBL] [Abstract][Full Text] [Related]
16. [Interaction of L-DOPA and pyridoxine (a review of the literature)].
Uspenskiĭ AE
Farmakol Toksikol; 1977; 40(6):722-33. PubMed ID: 340258
[No Abstract] [Full Text] [Related]
17. Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease.
Mars H
Trans Am Neurol Assoc; 1973; 98():241-5. PubMed ID: 4784941
[No Abstract] [Full Text] [Related]
18. Decarboxylation of orally administered L-dopa in the human digestive tract.
Bergmark J; Carlsson A; Granerus AK; Jagenburg R; Magnusson T; Svanborg A
Naunyn Schmiedebergs Arch Pharmacol; 1972; 272(4):437-40. PubMed ID: 4260263
[No Abstract] [Full Text] [Related]
19. Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent L-3,4-dihydroxyphenylalanine administration.
Lee WY; Lee EA; Jeon MY; Kang HY; Park YG
Exp Neurol; 2006 Jan; 197(1):215-24. PubMed ID: 16269145
[TBL] [Abstract][Full Text] [Related]
20. Clinical and cerebrospinal fluid changes in parkinsonian patients treated with L-3,4-dihydroxyphenylalanine (L-dopa).
Sharpless NS; Ericsson AD; McCann DS
Neurology; 1971 May; 21(5):540-9. PubMed ID: 5104098
[No Abstract] [Full Text] [Related]
[Next] [New Search]
